Dicerna Pharmaceuticals, Inc.Company Review & Valuation

DRNA
Nasdaq
Latest Price
36.94USD
Market Capitalization
2,840.69mUSD

About Dicerna Pharmaceuticals, Inc.

Dicerna Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery and development of pharmaceuticals for the treatment of rare, viral infectious, chronic liver, and cardiovascular diseases. Its development programs include DCR-PHXC for the treatment of primary hyperoxaluria; DCR-HShow more BVS for the treatment of chronic hepatitis B virus infection; and DCR-PCSK9 to treat hypercholesterolemia. The company has a collaborative research and license agreement with Boehringer Ingelheim International GmbH; a research collaboration and license agreement with Kyowa Hakko Kirin Co., Ltd.; and a license agreement with City of Hope. Dicerna Pharmaceuticals, Inc. was founded in 2006 and is headquartered in Cambridge, Massachusetts. Show less

Industry
Biotechnology
HQ Location
Cambridge, Massachusetts

Stock Price

Price data not available for Dicerna Pharmaceuticals, Inc..

Performance

Please login or create a free account to view the contents of this section.

Financial Reports

Please login or create a free account to view the contents of this section.

Similar Companies

back to top